POPULARITY
2 episodes with ips cells
2 episodes with ips cells
2 episodes with ips cells
2 episodes with ips cells
2 episodes with ips cells
2 episodes with ips cells
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
A Japanese research group has said that it became the world's first to succeed in producing regulatory T cells, which suppress excessive immune responses, from human induced pluripotent stem, or iPS, cells.
The heart function of crab-eating macaques that had experienced heart attacks returned after transplants of clusters of heart muscle cells made from human induced pluripotent stem, or iPS, cells, a Japanese research team said Friday.
As our bodies age, our cells are aging with us, and the messages they produce are decreasing. While growth factors have been used to take the message of youthful cells and use them to stimulate the skin, exosomes offer a more complete, natural, and protected version of those messages. Scientific researcher Dr. Jordan Plews, CEO and co-founder of ELEVAI Labs, joins Dr. Bass to discuss what's happening in the space of exosomes, stem cells, and regenerative medicine as a whole. Through experiments with stem cells, Dr. Plews and his colleagues discovered that the cells provided some benefit, but they weren't sticking around or fixing problems such as wounds. This led to the discovery of exosomes, nano-packages that the body uses to send signals to cells. When searching for the best exosomes to separate, Dr. Plews and his team found that by taking exosomes from age zero stem cells, they can safely be put back into the body to “remind it how to be young again.” Drawing on his two decades of research in the study of stem cells and regenerative medicine, Dr. Plews explains what exosomes are, how they were discovered, the potential they hold, and how we may be using them in medicine going forward. About Dr. Jordan Plews Dr. Jordan Plews is the co-founder and CEO of ELEVAI Labs, Inc. He has dedicated nearly 20 years to the study of stem cells and regenerative medicine. Following many years investigating the use of various types of stem cells on injury and degenerative diseases, he has gone on to build and lead teams, setting up stem cell culture labs and developing stem cell-based regenerative medicine solutions before pivoting into aesthetics. Learn more about Dr. Jordan Plews and ELEVAI Labs, Inc. Follow Dr. Plews on Instagram About Dr. Lawrence Bass Innovator. Industry veteran. In-demand Park Avenue board certified plastic surgeon, Dr. Lawrence Bass is a true master of his craft, not only in the OR but as an industry pioneer in the development and evaluation of new aesthetic technologies. With locations in both Manhattan (on Park Avenue between 62nd and 63rd Streets) and in Great Neck, Long Island, Dr. Bass has earned his reputation as the plastic surgeon for the most discerning patients in NYC and beyond. To learn more, visit the Bass Plastic Surgery website or follow the team on Instagram @drbassnyc Subscribe to the Park Avenue Plastic Surgery Class newsletter to be notified of new episodes & receive exclusive invitations, offers, and information from Dr. Bass.
Amander Clark, Ph.D., delves into crafting artificial ovaries for fertility and aging research. She stresses the importance of diversity in stem cell studies to ensure comprehensive findings. By assembling ovarian models from various genetic backgrounds, her team aims for inclusive representation in biomedical research, potentially offering insights into reproductive health and disease. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 38334]
Amander Clark, Ph.D., delves into crafting artificial ovaries for fertility and aging research. She stresses the importance of diversity in stem cell studies to ensure comprehensive findings. By assembling ovarian models from various genetic backgrounds, her team aims for inclusive representation in biomedical research, potentially offering insights into reproductive health and disease. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 38334]
Amander Clark, Ph.D., delves into crafting artificial ovaries for fertility and aging research. She stresses the importance of diversity in stem cell studies to ensure comprehensive findings. By assembling ovarian models from various genetic backgrounds, her team aims for inclusive representation in biomedical research, potentially offering insights into reproductive health and disease. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 38334]
Amander Clark, Ph.D., delves into crafting artificial ovaries for fertility and aging research. She stresses the importance of diversity in stem cell studies to ensure comprehensive findings. By assembling ovarian models from various genetic backgrounds, her team aims for inclusive representation in biomedical research, potentially offering insights into reproductive health and disease. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 38334]
Amander Clark, Ph.D., delves into crafting artificial ovaries for fertility and aging research. She stresses the importance of diversity in stem cell studies to ensure comprehensive findings. By assembling ovarian models from various genetic backgrounds, her team aims for inclusive representation in biomedical research, potentially offering insights into reproductive health and disease. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 38334]
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.10.528087v1?rss=1 Authors: Zhou, Z., Kakegawa, W., Fujimori, K., Sho, M., Shimamura, R., Supakul, S., Yoshimatsu, S., Kohyama, J., Yuzaki, M., Okano, H. Abstract: Cortical excitatory neurons (Cx neurons) are the most dominant neuronal cell type in the cerebral cortex and play a central role in cognition, perception, intellectual behavior, and emotional processing. Robust in vitro induction of Cx neurons may facilitate as a tool for the elucidation of brain development and the pathomechanism of the intractable neurodevelopmental and neurodegenerative disorders, including Alzheimers disease, and thus potentially contribute to drug development. Here, we report a defined method for the efficient induction of Cx neurons from the feeder-free-conditioned human embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells). Using this method, human ES/iPS cells could be differentiated into ~99% MAP2-positive neurons by three weeks, and these induced neurons displayed several characteristics of mature excitatory neurons within 5 weeks, such as strong expression of glutamatergic neuron-specific markers (subunits of AMPA and NDMA receptors and CAMKII), highly synchronized spontaneous firing and excitatory postsynaptic current (EPSC). In addition, the Cx neurons showed susceptibility to A{beta} oligomer toxicity and excessive glutamate excitotoxicity, which is another advantage for toxicity testing and searching for therapeutic agent discovery. Taken together, this study provides a novel research platform for studying neural development and degeneration based on the feeder-free human ES/iPS cell system. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Jeffrey Magee, M.D., Ph.D., of Washington University in St. Louis, discusses how mechanisms that regulate hematopoietic stem cells change with age and how this shapes the biology of pediatric leukemia. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38398]
Last month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday afternoon, Scott Friedman chaired an abstract session discussing advances in the basic science of researching and understanding mechanisms surrounding fibrosis and stellate cells. Later, he described it as "one of the most exciting groups of presentations I've seen in many years." This conversation centers on papers with similar methods and processes for researching stellate cells.Scott begins this conversation by describing this process, which is based on another Nobel Prize-winning methodology. In this technique, the researchers start by forcing an adult mature skin cell (or any cell, for that matter) o express a cluster of very well-defined genes and transcription factors, which the researcher then turns into a generalized, Induced Pluripotent Stem (IPS) cell. Researchers have found ways to convert these IPS cells into stellate cells. The developer of this technique posited that it will enable us to explore the proteome. To Scott, this process of converting a generalized cell to a stellate cell we can analyze via proteomics to find new targets is more important and noteworthy than the result of this specific study (researchers identified a novel nuclear receptor called RORalpha). To quote Scott, "they're much closer to the action when they find a protein rather than just the mRNA that encodes it." He goes on to discuss a second study from Insitro (a company with which he consults) about their work seeking to optimize the IPS-derived stellate cells to find the one that most closely resembles cells in vivo. When Scott finishes, Neil notes that single-cell proteomics is not "coming, but it's not there yet." Neil anticipates we will have this pivotal tool available in a 1-2 year time horizon. Next, Jörn anticipates and asks about the next stage in the process: identifying a protein related to this process we can find in peripheral blood given that, as Neil noted, tissue sampling in the clinical setting will not be possible. Scott discusses a recent paper that seems to provide a solution to this issue in breast cancer. While he notes that the work has to be validated first, it clearly suggests researchers are close to finding proteins we can identify in blood in at least one cancer-related case. From there, Scott turns to Rachel for feedback, since this is the area in which her business is building its research. Her answer has several elements to it, but the main point is that proteomic development lags behind some of the other techniques but is making rapid advances as the costs of some key analytical processes come down. She then goes on to provide a description of epigenetics, the area in which she works most intensively.
On this week's Tech Nation, University of Pennsylvania professors Michael Kearns and Aaron Roth with their book, “The Ethical Algorithm … the science of socially aware algorithm design.” Then regular contributor Gary Davis reports in on the state of Corporate Security breaches, and Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about IPS Cells – having our own cells treat our bodies.
On this week’s Tech Nation, University of Pennsylvania professors Michael Kearns and Aaron Roth with their book, “The Ethical Algorithm … the science of socially aware algorithm design.” Then regular contributor Gary Davis reports in on the state of Corporate Security breaches, and Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about IPS Cells – having our own cells treat our bodies.
We take a trip back to the womb and before, to find out about early development. Plus, the importance of placentas, why the age of your womb rather than your eggs matters, and a video game-inspired gene of the month. Like this podcast? Please help us by supporting the Naked Scientists
We speak to scientists turning embryonic cells into nerve cells to treat Parkinson's disease and growing an entire system of organs in the lab. Plus, how antibiotics taken during pregnancy may affect your child's behaviour and why climate change will lead to bumpier flights. Like this podcast? Please help us by supporting the Naked Scientists
We speak to scientists turning embryonic cells into nerve cells to treat Parkinson's disease and growing an entire system of organs in the lab. Plus, how antibiotics taken during pregnancy may affect your child's behaviour and why climate change will lead to bumpier flights. Like this podcast? Please help us by supporting the Naked Scientists
Guest Dr. Scott Noggle, VP of Stem Cell Research at The New York Stem Cell Foundation discusses his automated system for making iPS cells. Dr. Noggle applies new advances in pluripotent stem cell biology and…
The cocktail party effect and how the brain decides which sounds to attend to, genes dismissed as dead relics turn out to play significant roles in inflammation, iPS cells reproduce degenerative retinal disease, the genetic responses to flu jabs, and the discovery of stem cells in schistosomes... Get the references and the transcripts for this programme from the Naked Scientists website
Scientific American Editor in Chief Mariette DiChristina talks with podcast host Steve Mirsky about the contents of the May issue, including articles on induced pluripotent stem cells, high-speed and maglev trains, and blindsight. Plus, we'll test your knowledge of some recent science in the news
© 2020-2025 Ivy Podcast Discovery LLC
